Reality Check on Type 2 Diabetes (GLP-1 and Combo)
Market access for type 2 Diabetes (GLP-1 and Combo) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, almost 46% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: Access to Novo Nordisk’s Rybelsus (semaglutide) — the first oral glucagon-like peptide-1 receptor agonist (GLP-1) to treat adults with type 2 diabetes — got a major boost in January 2020 when Novo said Express Scripts, part of Cigna Corp., would cover the agent
- Key Findings: Coverage for the drugs is via the pharmacy benefit. This is a heavily contracted class; costs are high, but so are rebates. Step-therapy restrictions are common, either alone or as part of prior authorization
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.